Sacubitril/Valsartan and Right Ventricular and Diastolic Function During Breast Cancer Therapy

Q: What is the clinical evidence from this study?

Study design: RCT. Population: Breast cancer receiving adjuvant anthracycline-based chemotherapy (n=138). Intervention: Sacubitril/valsartan vs. Placebo. Primary outcome: Change in right ventricular systolic velocity (RV S′) from baseline to 18 months (MD 1.28 cm/s, 95% CI 0.43-2.13, p=0.003).

Q: What does this research mean for the field?

Sacubitril/valsartan attenuates subclinical declines in right ventricular systolic function in women receiving anthracycline-based chemotherapy for breast cancer. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

Mari Nordbø Gynnild; Albulena Mecinaj Lilleaasen; Torgeir Wethal; Even O. Jakobsen; Victoria Vinje-Jakobsen; Siri Lagethon Heck; Stian Larsen; Assami Rösner; Håvard Dalen; Torbjørn Omland; Geeta Gulati; Espen Holte

doi:10.1016/j.jaccao.2026.06.002

August 1, 2026JACC CardioOncologyOpen Access

Sacubitril/Valsartan and Right Ventricular and Diastolic Function During Breast Cancer Therapy

View Full Paper

Ask AI

Bookmark

Share

Figures

Graphical abstract published by JACC CardioOncology — Graphical abstract · Published by JACC CardioOncology · CC BY

Study Design

Type

RCT (n=138)

Blinding

Double-blind

Randomization

Randomized

Multicenter

Yes

PICO

P

Population

138 women receiving adjuvant anthracycline-based chemotherapy for breast cancer, randomized to sacubitril/valsartan or placebo and followed for 18 months.

I

Intervention / Comparator

Sacubitril/valsartan vs Placebo (97/103 mg twice daily)

O

Primary Outcome

Change in right ventricular systolic velocity (RV S′) from baseline to 18 months — MD 1.28 cm/s (0.43-2.13), p=0.003

Main Result

Mean Difference: 1.28 (95% CI 0.43–2.13)

Absolute Event Rate: 0.6% vs -0.7%

p-value: p=0.003

Limitations

Predominantly low-risk population with preserved baseline cardiac function
Clinical relevance of modest echocardiographic findings remains uncertain
Requires confirmation in larger studies enrolling higher-risk populations

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

May support RV assessment in cardio-oncology trials; leaves open clinical benefit of sacubitril/valsartan in anthracycline recipients.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gynnild et al. (2026) conducted an RCT in Breast cancer receiving adjuvant anthracycline-based chemotherapy (n=138). Sacubitril/valsartan vs. Placebo was evaluated on Change in right ventricular systolic velocity (RV S′) from baseline to 18 months (MD 1.28 cm/s, 95% CI 0.43-2.13, p=0.003).

synapsesocial.com/papers/6aa6d9b7041e43fea73a8608 https://doi.org/10.1016/j.jaccao.2026.06.002

View Full Paper

Ask AI

Bookmark

Share

Sacubitril/Valsartan and Right Ventricular and Diastolic Function During Breast Cancer Therapy

Figures

Study Design

PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Sacubitril/Valsartan and Right Ventricular and Diastolic Function During Breast Cancer Therapy

Figures

Study Design

PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading